Endometriosis affects roughly one in ten women of reproductive age globally, yet treatment options remain stubbornly limited to hormonal suppression or repeated surgeries — neither of which addresses the underlying inflammatory biology driving lesion growth and chronic pelvic pain. A new molecular target-and-drug approach published in PNAS suggests that selectively silencing a specific kinase pathway could offer a fundamentally different therapeutic angle.
Using DNA-encoded chemistry — a high-throughput screening method capable of interrogating millions of compounds simultaneously — researchers identified potent small-molecule inhibitors of JUN N-terminal kinases (JNKs), a family of stress-activated protein kinases implicated in the inflammatory signaling cascades that sustain endometriotic lesions. The study characterizes lead compounds with defined binding affinity and selectivity profiles and evaluates their efficacy in preclinical endometriosis models, reporting measurable reductions in lesion burden and pain-associated behavioral endpoints. The JNK pathway has been shown in prior work to regulate prostaglandin synthesis and pro-inflammatory cytokine production in endometrial stromal cells, which may explain the dual benefit on tissue growth and pain signaling.
This research sits within a wider effort to reframe endometriosis as a chronic inflammatory disease rather than purely a gynecological anatomical problem — a shift that opens the door to systemic pharmacological intervention. JNK inhibitors have been explored for oncology and neuroinflammation, but translation to endometriosis is relatively novel. The key limitation here is that preclinical models, however well-designed, imperfectly replicate the hormonal complexity of human endometriosis. No human trial data yet exist for this compound class in this indication. Still, the use of DNA-encoded library screening represents a methodologically rigorous discovery platform, and the dual pain-plus-lesion efficacy signal makes this incrementally more than routine target validation — a credible early-stage candidate warranting careful clinical development.